Pharmac has included the weight-loss drug Wegovy in its future funding list, with eligibility based on BMI and comorbidities, amid concerns over cost and effectiveness.
Stacked weekly counts; colour by editorial lean. Stuff and The Spinoff lean centre-left, NZ Herald centre-right, others centre.
How press outlets have named this topic, week by week.
Most recent 1 articles linking to this topic.
Up to 12 framings spread across outlets. Each framing is the LLM's one-line characterisation of the article's editorial angle — not a quote.
shift from bmi 30 to 35 as benchmark
Pharmac adds Wegovy for weight loss to list for future fundingSpotted something wrong on this page? Report a correction.